Local and systemic functions of bone fat and its contribution to the energy metabolism - The effect of diabetes and obesity on bone

Journal of Musculoskeletal Neuronal Interactions

Volumn 8, Issue 4, 2008, Pages 346-347

  Lecka Czernik, Beata ^a  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

Author keywords

Adipokines; Bone; Diabetes; Fat; PPAR ; Thiazolidinediones

Indexed keywords

ADIPONECTIN; GLITAZONE DERIVATIVE; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; RESISTIN;

ADIPOCYTE; ADIPOGENESIS; AGING; ATTRIBUTABLE RISK; BONE MASS; BONE METABOLISM; CELL DIFFERENTIATION; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG TARGETING; ENERGY EXPENDITURE; ENERGY METABOLISM; FRACTURE; GLUCOSE METABOLISM; HORMONE ACTION; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; METABOLIC REGULATION; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; SIDE EFFECT;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; BONE AND BONES; DIABETES MELLITUS; ENERGY METABOLISM; HUMANS; OBESITY;

EID: 63249117109     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Lecka-Czernik B, Gubrij I, Moerman EA, Kajkenova O, Lipschitz DA, Manolagas SC, Jilk RL. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ 2. J Cell Biochem 1999; 74:357-71.
2. Wan Y, Chong LW, Evans RM. PPARγ regulates osteociastogenesis in mice. Nat Med 2007;13:1496-503.
3. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPARγ2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004; 3:379-89.
4. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007;148:2669-80.
5. Schwartz AV, Sellmeyer DE, Strotmeyer ES, Tylavsky FA, Feingold KR, Resnick HE, Shorr RI, Nevitt MC, Black DM, Cauley JA, Cummings SR, Harris TB. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 2005;20:596-603.
6. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:32-8.
7. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51.
8. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Won Park S, Lane NE, Harris TB, Cummings SR. Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54.
9. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the anti-diabetic compound rosiglitazone. Endocrinology 2004;145:401-6.
10. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002;143-2376-84.
11. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B. Netoglitazone is a PPARγ ligand with selective effects on bone and fat. Bone 2006; 38:74-85.